NASDAQ:ZIOPZIOPHARM Oncology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ZIOPHARM Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.96 -0.11 (-3.58 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$2.90Now: $2.96▼$3.2150-Day Range$2.54MA: $2.86▼$3.4952-Week Range$1.79Now: $2.96▼$7.25Volume2.04 million shsAverage Volume1.72 million shsMarket Capitalization$634.30 millionP/E RatioN/ADividend YieldN/ABeta2.5 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, to treat patients with recurrent glioblastoma and breast cancer. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; research and development agreement with the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingZIOPHARM Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.67, ZIOPHARM Oncology has a potential upside of 91.4% from its current price of $2.96.Amount of Analyst CoverageZIOPHARM Oncology has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesZIOPHARM Oncology has received 376 “outperform” votes. (Add your “outperform” vote.)Underperform VotesZIOPHARM Oncology has received 405 “underperform” votes. (Add your “underperform” vote.)Community SentimentZIOPHARM Oncology has received 51.86% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote “Outperform” if you believe ZIOP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldZIOPHARM Oncology does not currently pay a dividend.Dividend GrowthZIOPHARM Oncology does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ZIOPHARM Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of ZIOPHARM Oncology is held by insiders.Percentage Held by Institutions46.21% of the stock of ZIOPHARM Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ZIOPHARM Oncology are expected to decrease in the coming year, from ($0.36) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ZIOPHARM Oncology is -4.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ZIOPHARM Oncology is -4.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZIOPHARM Oncology has a P/B Ratio of 3.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.38 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ZIOP Previous Symbol CUSIP98973P10 CIK1107421 Webwww.ziopharm.com Phone617-259-1970Debt Debt-to-Equity Ratio0.01 Current Ratio11.56 Quick Ratio11.56Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$150,000.00 Price / Sales4,228.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.84 per share Price / Book3.52Profitability EPS (Most Recent Fiscal Year)($0.34) Net Income$-117,800,000.00 Net MarginsN/A Return on Equity-56.00% Return on Assets-49.81%Miscellaneous Employees48 Outstanding Shares214,290,000Market Cap$634.30 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:ZIOP Rates by TradingView Receive ZIOP News and Ratings via Email Sign-up to receive the latest news and ratings for ZIOP and its competitors with MarketBeat's FREE daily newsletter. ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions How has ZIOPHARM Oncology's stock been impacted by COVID-19 (Coronavirus)? ZIOPHARM Oncology's stock was trading at $2.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ZIOP shares have increased by 16.5% and is now trading at $2.96. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of ZIOPHARM Oncology? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ZIOPHARM Oncology. When is ZIOPHARM Oncology's next earnings date? ZIOPHARM Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for ZIOPHARM Oncology. How were ZIOPHARM Oncology's earnings last quarter? ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) posted its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.09). During the same period in the prior year, the firm earned ($0.08) earnings per share. View ZIOPHARM Oncology's earnings history. What price target have analysts set for ZIOP? 3 Wall Street analysts have issued 1 year price objectives for ZIOPHARM Oncology's shares. Their forecasts range from $5.50 to $6.00. On average, they expect ZIOPHARM Oncology's stock price to reach $5.67 in the next year. This suggests a possible upside of 91.4% from the stock's current price. View analysts' price targets for ZIOPHARM Oncology. Has ZIOPHARM Oncology been receiving favorable news coverage? Media stories about ZIOP stock have trended positive this week, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ZIOPHARM Oncology earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutZIOPHARM Oncology. Who are some of ZIOPHARM Oncology's key competitors? Some companies that are related to ZIOPHARM Oncology include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors. What other stocks do shareholders of ZIOPHARM Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Celgene (CELG), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Opko Health (OPK), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Sangamo Therapeutics (SGMO). Who are ZIOPHARM Oncology's key executives? ZIOPHARM Oncology's management team includes the following people: Dr. Laurence James Neil Cooper, CEO & Director (Age 54)Dr. David M. Mauney M.D., Pres (Age 50)Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 63)Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.Mr. David Connolly, VP of Corp. Communications & Investor Relations What is ZIOPHARM Oncology's stock symbol? ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP." Who are ZIOPHARM Oncology's major shareholders? ZIOPHARM Oncology's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.55%), State Street Corp (2.99%), Geode Capital Management LLC (1.24%), Morgan Stanley (0.63%), Morgan Stanley (0.63%) and Bank of New York Mellon Corp (0.39%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney, Groot Eleanor De, Kevin G Lafond, Laurence James Neil Cooper and Robert Hadfield. View institutional ownership trends for ZIOPHARM Oncology. Which major investors are selling ZIOPHARM Oncology stock? ZIOP stock was sold by a variety of institutional investors in the last quarter, including Rafferty Asset Management LLC, Invesco Ltd., UBS Group AG, Sargent Investment Group LLC, Victory Capital Management Inc., Victory Capital Management Inc., Vident Investment Advisory LLC, and Virtus ETF Advisers LLC. Company insiders that have sold ZIOPHARM Oncology company stock in the last year include David M Md Mauney, Groot Eleanor De, Kevin G Lafond, Laurence James Neil Cooper, and Robert Hadfield. View insider buying and selling activity for ZIOPHARM Oncology. Which major investors are buying ZIOPHARM Oncology stock? ZIOP stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Geode Capital Management LLC, Two Sigma Investments LP, Morgan Stanley, Morgan Stanley, Advisor Group Holdings Inc., and Bank of New York Mellon Corp. View insider buying and selling activity for ZIOPHARM Oncology. How do I buy shares of ZIOPHARM Oncology? Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ZIOPHARM Oncology's stock price today? One share of ZIOP stock can currently be purchased for approximately $2.96. How big of a company is ZIOPHARM Oncology? ZIOPHARM Oncology has a market capitalization of $634.30 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-117,800,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. ZIOPHARM Oncology employs 48 workers across the globe. What is ZIOPHARM Oncology's official website? The official website for ZIOPHARM Oncology is www.ziopharm.com. How can I contact ZIOPHARM Oncology? ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected] This page was last updated on 6/1/2020 by MarketBeat.com Staff
